Ardea Biosciences

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Ardea Biosciences sits in the top decile of US sponsors by registered trial count (#513 of 15,742 sponsors by registered trial count).

32 total trials none currently recruiting 32 completed early-phase tilt top decile by trial count

Ardea Biosciences: 32 sponsored US clinical trials, none currently recruiting.

Ardea Biosciences sponsors 32 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 32 completed. 8 of these trials are in Phase 3-4 (later-stage) and 23 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Gout, with 3 trials.

Top-decile sponsor footprint

Ardea Biosciences ranks in the top decile of sponsors by registered trial count (#513 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

32 of 32 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

32 total, page 1 of 1

COMPLETED Phase 1

Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence

NCT02888054

COMPLETED Phase 1

RDEA3170 PK/PD Study

NCT02608710

COMPLETED Phase 1

Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability

NCT02581553

COMPLETED Phase 2

Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects

NCT02498652

COMPLETED Phase 1

RDEA3170 Tablet and Capsule Bioavailability Study

NCT02448368

COMPLETED

DECT Study in Allopurinol-Treated Gout Patients

NCT02393560

COMPLETED Phase 1

RDEA3170 and Allopurinol Combination Study in Gout Subjects

NCT02279641

COMPLETED Phase 1

RDEA3170 Bioavailability Study

NCT02336594

COMPLETED Phase 2

RDEA3170 and Febuxostat Combination Study in Gout Subjects

NCT02246673

COMPLETED Phase 1

Mild, Moderate and Severe Renal Impairment Study

NCT02219516

COMPLETED Phase 1

Lesinurad Tablet Bioequivalence

NCT02127775

COMPLETED Phase 1

Bioavailability of Lesinurad and Intravenous [14C]Lesinurad

NCT02039700

COMPLETED Phase 1

Antacid Interaction Study

NCT01982201

COMPLETED Phase 1

Lesinurad Tablet Relative Bioavailability

NCT01986556

COMPLETED Phase 1

Metformin and Furosemide Drug-Drug Interaction Study

NCT02028689

COMPLETED Phase 2

RDEA3170 Monotherapy in Subjects With Gout

NCT01927198

COMPLETED Phase 1

RDEA3170 AME Study

NCT01910506

COMPLETED Phase 1

Lesinurad Interaction Study With Ranitidine

NCT01908257

COMPLETED Phase 1

NSAID Drug Interaction Study

NCT01884272

COMPLETED Phase 1

RDEA3170 and Febuxostat Drug Interaction Study

NCT01883167

COMPLETED Phase 1

Single and Multiple Dose Study in Japanese Subjects

NCT01872832

COMPLETED Phase 3

Lesinurad and Febuxostat Combination Extension Study in Gout

NCT01808144

COMPLETED Phase 3

Lesinurad and Allopurinol Combination Extension Study in Gout

NCT01808131

COMPLETED Phase 1

Single and Multiple Dose Study in Japanese

NCT01744379

COMPLETED Phase 3

Open-Label Lesinurad Monotherapy Extension Study in Gout

NCT01650246

COMPLETED Phase 3

Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors

NCT01508702

COMPLETED Phase 3

Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat

NCT01510769

COMPLETED Phase 3

Combining Lesinurad With Allopurinol in Inadequate Responders

NCT01510158

COMPLETED Phase 3

Combining Lesinurad With Allopurinol in Inadequate Responders

NCT01493531

COMPLETED Phase 4

Allopurinol Outcome Study

NCT01391325

COMPLETED Phase 2

Allopurinol Combination Study

NCT01001338

COMPLETED Phase 2

Gout Dose Response Study

NCT00955981

Phase Distribution

PhaseTrial count
Phase 1 18
Phase 2 5
Phase 3 7
Phase 4 1

Therapeutic Areas

How the Ardea Biosciences early-phase archive is shaped

32 indexed studies, none listed as recruiting (0% open); 32 completed (100%).

Phase mix: 8 late (III/IV) vs 23 early (I/II) (early-phase heavy).

Top condition: Gout (3 trials), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Ardea Biosciences: archived-pipeline peers nationwide

Peers matched on 32 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Ardea Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 010203040 0%5%10%15%20% Total trials Recruiting share Ardea BiosciencesAerie PharmaceuticalsAllina Health SystemHebrew SeniorLifeMiMedx Group10xBio22nd Century Group23andMe3-C Institute for Social Development
Ardea Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Ardea Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 32 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Ardea Biosciences page

32 registered trials is a research-attention snapshot, not an endorsement of Ardea Biosciences or any single study.

  • None of Ardea Biosciences's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Gout is the condition Ardea Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Gout trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Ardea Biosciences pipeline card: 32 registered trials from official public datasets.Report a data error.